Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Takeshi Ito | President, CEO & Representative Director | 1.07M | -- | 1959 |
| Mr. Kazuo Koshiji | CFO & Corporate Officer | -- | -- | -- |
| Ms. Rie Nakajima | COO, Corporate Officer & Director | -- | -- | 1977 |
| Ms. Kaori Itagaki | General Manager of Investor Relations Group | -- | -- | -- |
| Ms. Mika Masunari | General Counsel & Chief Compliance Officer | -- | -- | -- |
| Ms. Nobuko Kato | Chief Communications Officer | -- | -- | -- |
| Mr. Shinichi Teramachi | Corp. Officer, Head of Sales and Head of Japan Sales & Marketing | -- | -- | -- |
| Mr. Kenji Morishima | Corporate Officer & Head of China Product Development Department | -- | -- | -- |
| Mr. Takahiro Morita | Global Head of Core Principle & Sustainability and Corporate Officer | -- | -- | -- |
| Mr. Frank Binder | Corporate Officer & Head of Supply Chain Division | -- | -- | -- |
Santen Pharmaceutical Co., Ltd.
- Sector:
- Healthcare
- Industry: Drug Manufacturers - General
- Full Time Employees:
- 3,744
Description
Santen Pharmaceutical Co., Ltd. engages in the research and development, manufacture, and marketing of pharmaceuticals and medical devices in Japan and internationally. Its product portfolio includes tafluprost/timolol maleate, a prostaglandin F2a derivative and a beta-adrenergic receptor blocker; and netarsudil mesilate and latanoprost, a prostaglandin F2a derivative which is marketing approval phase for the treatment of glaucoma and ocular hypertension. The company also offers sepetaprost, a prostaglandin analogue eye drop drug that is in phase 3 of clinical trials; and latanoprost, an ophthalmic emulsion of a prostaglandin F2a derivative which is filed for marketing approval for the treatment of glaucoma and ocular hypertension. In addition, it provides cyclosporin, an ophthalmic emulsion for the treatment of vernal keratoconjunctivitis; and diquafosol sodium for dry eye treatment. Further, the company develops olodaterol hydrochloride, a ß2 receptor agonist that is in phase 1/2a for the treatment of A dry eye treatment dry eye; sirolimus, an ophthalmic suspension which is in phase 2a for the treatment of 4 Fuchs endothelial corneal dystrophy and meibomian gland dysfunction; epinastine hydrochloride, a histamine H1 receptor antagonist filed for marketing approval for the treatment of allergic conjunctivitis; atropine sulfate, a non-selective muscarinic antagonist that is in phase 2/3 clinical trials for myopia treatment; and AFDX0250BS, an selective muscarinic M2 antagonist which is in phase 2a for the treatment of myopia. Additionally, it offers ursodeoxycholic acid that is in phase 2a of clinical trial for the treatment of presbyopia; and oxymetazoline hydrochloride, a direct-acting alpha adrenergic receptor agonist which is in phase 3 for treatment of ptosis. The company was founded in 1890 and is headquartered in Osaka, Japan.
Corporate Governance
Upcoming Events
May 7, 2025 at 6:00 AM UTC - May 12, 2025 at 6:00 AM UTC
Santen Pharmaceutical Co., Ltd. Earnings Date
Recent Events
March 28, 2025 at 12:00 AM UTC
Ex-Dividend Date